Literature DB >> 28478948

Final height and intrauterine growth retardation.

Maïthé Tauber1.   

Abstract

Approximately 10% of small for gestational age (SGA) children maintain a small body size throughout childhood and often into adult life with a decreased pubertal spurt. Growth hormone (GH) therapy increases short-term growth in a dose-dependent manner and adult height had now been well documented. Shorter children might benefit from a higher dose at start (50μg/kg/day). The response to GH treatment was similar for both preterm and term short SGA groups and the effect of GH treatment on adult height showed a wide variation in growth response. As a whole, mean adult height is higher than -2 SDS in 60% of patients and 70% reached an adult height in their target height with better results with higher doses and combined GnRH analog therapy in those who were short at onset of puberty.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Adult height; Final height; Growth hormone treatment (GH); Intrauterine growth retardation (IUGR); Petit pour l’âge gestationnel; Retard de croissance intra-utérin (RCIU); Small for gestational age (SGA); Taille adulte; Taille finale; Traitement par hormone de croissance

Mesh:

Substances:

Year:  2017        PMID: 28478948     DOI: 10.1016/j.ando.2017.04.005

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  1 in total

1.  Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age.

Authors:  Mieczyslaw Walczak; Mieczyslaw Szalecki; Gerd Horneff; Jan Lebl; Barbara Kalina-Faska; Tomasz Giemza; Florentina Moldovanu; Michaela Nanu; Hichem Zouater
Journal:  Ther Adv Endocrinol Metab       Date:  2021-05-05       Impact factor: 3.565

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.